China grants country's first Covid-19 vaccine patent to CanSino: state media
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
[BEIJING] China's vaccine specialist CanSino Biologics Inc has won a patent approval from Beijing for its Covid-19 vaccine candidate Ad5-nCOV, state media reported, citing documents from the country's intellectual property regulator.
It is the first Covid-19 vaccine patent granted by China, state-owned newspaper People's Daily reported on Sunday.
The paper cited documents published by China's National Intellectual Property Administration saying that the patent was issued on Aug 11.
Saudi Arabia said this month it plans to begin Phase III clinical trials for the CanSino vaccine. CanSino has said it is also in talks with Russia, Brazil and Chile to launch Phase III trials in those countries.
CanSino's Hong Kong shares rose around 14 per cent in Monday's morning session. Its Shanghai shares rose by 6.6 per cent as of midday.
REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Eurokars Group introduces rental car franchises Enterprise Rent-A-Car, National Car Rental, and Alamo to Singapore
20 photos that show how dramatically Singapore has changed in two decades
Singapore’s key exports up 15.3% in March from electronics surge, exceeding forecasts
